Suppr超能文献

源自视网膜蛋白IRBP的合成肽的免疫学特征:免疫显性肽与非显性肽之间的差异

Immunological features of synthetic peptides derived from the retinal protein IRBP: differences between immunodominant and non-dominant peptides.

作者信息

Lipham W J, Sanui H, Redmond T M, Wiggert B, de Smet M D, Chader G J, Gery I

机构信息

National Eye Institute, NIH, Bethesda, MD 20892.

出版信息

Curr Eye Res. 1990 Jan;9(1):95-8. doi: 10.3109/02713689009000059.

Abstract

Interphotoreceptor retinoid-binding protein (IRBP) is a glycoprotein of 1264 residues (bovine) which localizes specifically in the retina and pineal gland and induces inflammatory changes in these organs (EAU and EAP, respectively) in immunized animals. We report here on differences between the immunological activities in Lewis rats of four IRBP-derived synthetic peptides. Only one of these peptides, designated R14 (residues: 1169-1191) is immunodominant, i.e., it has the capacity to stimulate lymphocytes sensitized against whole IRBP. The remaining peptides, R4 (1158-1180), R8 (1197-1209), and R12 (248-266), are non-dominant and are not recognized by IRBP-sensitized lymphocytes. R14 differed profoundly from the other peptides in its immunogenicity, inducing cellular immunity at the low dose of 0.1 nmol/rat, whereas the non-dominant peptides initiated immune responses at doses approximately 100 times higher. R14 was also superior to the non-dominant peptides in its antigenicity, as determined by the lowest concentration required to induce sensitized lymphocytes to proliferate. Responses were stimulated by R14 at a concentration of 10(-6) microM, while the three non-dominant peptides were stimulatory at the much higher concentration of 10(-1) microM. These data support the concept that immunodominance is linked to a high binding affinity of the peptide determinant to the major histocompatibility complex antigens on antigen-presenting cells.

摘要

视网膜色素上皮结合蛋白(IRBP)是一种由1264个氨基酸残基组成的糖蛋白(牛源),它特异性地定位于视网膜和松果体,并在免疫动物的这些器官中诱导炎症变化(分别为实验性自身免疫性葡萄膜炎和实验性自身免疫性松果体炎)。我们在此报告四种IRBP衍生的合成肽在Lewis大鼠中的免疫活性差异。这些肽中只有一种,命名为R14(氨基酸残基:1169 - 1191)具有免疫优势,即它有能力刺激针对完整IRBP致敏的淋巴细胞。其余的肽,R4(1158 - 1180)、R8(1197 - 1209)和R12(248 - 266)不具有优势,且不被IRBP致敏的淋巴细胞识别。R14在免疫原性方面与其他肽有很大不同,以0.1 nmol/大鼠的低剂量就能诱导细胞免疫,而非优势肽引发免疫反应所需的剂量大约高100倍。R14在抗原性方面也优于非优势肽,这是通过诱导致敏淋巴细胞增殖所需的最低浓度来确定的。R14在10^(-6) microM的浓度下就能刺激反应,而三种非优势肽在10^(-1) microM的高得多的浓度下才有刺激作用。这些数据支持了免疫优势与肽决定簇对抗抗原呈递细胞上主要组织相容性复合体抗原的高结合亲和力相关的概念。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验